Àΰ£¸é¿ª°áÇ̹ÙÀÌ·¯½º Ä¡·áÁ¦ ½ÃÀå ±âȸ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м® ¹× ¿¹Ãø(2025-2034³â)
Human Immunodeficiency Virus Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
»óǰÄÚµå : 1665059
¸®¼­Ä¡»ç : Global Market Insights Inc.
¹ßÇàÀÏ : 2024³â 12¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 145 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,850 £Ü 6,882,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,050 £Ü 8,585,000
PDF & Excel (Multi User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,350 £Ü 11,849,000
PDF & Excel (Enterprise User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ Àΰ£¸é¿ª°áÇ̹ÙÀÌ·¯½º Ä¡·áÁ¦ ½ÃÀåÀº 2024³â¿¡ 390¾ï ´Þ·¯ÀÇ Æò°¡¾×¿¡ À̸£·¶°í, 2025³âºÎÅÍ 2034³â±îÁö ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR) 3.5%À» ³ªÅ¸³»¸ç ¾ÈÁ¤ÀûÀÎ ¼ºÀåÀ» ÀÌ·ê °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

½ÃÀå È®´ëÀÇ ÁÖ¿ä ¿äÀÎÀº HIV °¨¿°·üÀÇ »ó½Â, Ä¡·á¹ýÀÇ ´ëÆøÀûÀÎ Áøº¸, Á¤ºÎÀÇ Àû±ØÀûÀÎ ³ë·Â, À¯¸®ÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ µîÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ °áÇÕµÇ¾î ½ÃÀåÀÇ Áö¼ÓÀûÀÎ ¼ºÀå ±Ëµµ¸¦ ÃËÁøÇϴµ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù.

Human Immunodeficiency Virus Therapeutics Market-IMG1

½ÃÀåÀº ÁÖ·Î ¾à¹°ÀÇ À¯Çü¿¡ µû¶ó ºê·£µå ÀǾàǰ°ú Á¦³×¸¯ ÀǾàǰÀ¸·Î ±¸ºÐµË´Ï´Ù. 2024³â¿¡´Â ºê·£µå ÀǾàǰÀÌ 74.5%¶ó´Â ´ëÆøÀûÀÎ Á¡À¯À²·Î ½ÃÀåÀ» ¼±µµÇßÀ¸¸ç, ±× ÀÌÀ¯´Â È¿´ÉÀÌ ÀÔÁõµÈ °Í, ¿À·£ ÀÓ»óÀû ½Å·Ú¼ºÀÌ ÀÖ´Â °Í, HIV Ä¡·á¿¡ À־ÀÇ ½ÇÀûÀÌ ½Å·ÚµÇ¾ú±â ¶§¹®ÀÔ´Ï´Ù. ÇÕÁ¦´Â Åõ¾à ¿ä¹ýÀ» ´Ü¼øÈ­Çϰí ȯÀÚÀÇ Ä¡·á °èȹ¿¡ ´ëÇÑ Ãæ°ÝÀ» ³ôÀ̱⠶§¹®¿¡ ³Î¸® º¸±ÞµÇ¾î ÀÖ½À´Ï´Ù. ƯÈ÷ ¹ÙÀÌ·¯½º·®À» È¿°úÀûÀ¸·Î ¾ïÁ¦Çϱâ À§ÇÑ º´¿ë¿ä¹ý¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀº ½ÃÀå ¼ö¿ä¸¦ °è¼Ó °ßÀÎÇϰí ÀÖÀ¸¸ç, ÇâÈÄ ¼ö³â°£ ½ÃÀåÀÇ ¾ÈÁ¤ÀûÀÎ ¼ºÀåÀ» È®½ÇÈ÷ Çϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¹üÀ§
½ÃÀÛ ¿¬µµ 2024³â
¿¹Ãø ¿¬µµ 2025-2034³â
½ÃÀÛ ±Ý¾× 390¾ï ´Þ·¯
¿¹Ãø ±Ý¾× 548¾ï ´Þ·¯
CAGR 3.5%

½ÃÀå À¯Åë ä³ÎÀº HIV Ä¡·áÁ¦ÀÇ µµ´Þ¹üÀ§¿Í Á¢±Ù¼ºÀ» ´õ¿í µ¸º¸ÀÌ°Ô ÇÕ´Ï´Ù. ÁÖ¿ä À¯Åë ºÎ¹®¿¡´Â ¾à±¹°ú ¼Ò¸Å ¾à±¹, ¿Â¶óÀÎ ¾à±¹ ¹× º´¿ø ¾à±¹ÀÌ Æ÷ÇԵ˴ϴÙ. 2024³â¿¡´Â º´¿ø ¾à±¹ÀÌ 47.4%·Î ½ÃÀå ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. º´¿ø ¾à±¹Àº °í±Þ Ç× ·¹Æ®·Î ¹ÙÀÌ·¯½º ¿ä¹ý°ú ½ÅÁßÇÑ Åõ¿©°¡ ÇÊ¿äÇÑ ÁÖ»ç Ä¡·á¸¦ Æ÷ÇÔÇÏ¿©º¸´Ù ±¤¹üÀ§ÇÑ Àü¹® HIV Ä¡·áÁ¦¸¦ Á¦°øÇϱâÀ§ÇÑ ½Ã¼³À» °®Ãß°í ÀÖ½À´Ï´Ù. ÀÇ·á Àü¹®°¡ÀÇ °¨µ¶ÇÏ¿¡, º´¿ë ¿ä¹ýÀ» Æ÷ÇÔÇÑ ÃÖ÷´Ü Ä¡·á¸¦ Á¦°øÇÒ ¼ö Àֱ⠶§¹®¿¡ Àü¹®ÀûÀÎ Äɾî¿Í ¹è·Á°¡ ÇÊ¿äÇÑ È¯ÀÚ¿¡°Ô ¹Ù¶÷Á÷ÇÑ ¼±ÅÃÀÌ µÇ°í ÀÖ½À´Ï´Ù.

¹Ì±¹¿¡¼­ HIV Ä¡·áÁ¦ ½ÃÀåÀº 2024³â¿¡ 145¾ï ´Þ·¯¸¦ âÃâÇß½À´Ï´Ù. ÀÌ ³ª¶ó´Â °íµµ·Î ¹ß´ÞÇÑ ÀÇ·á ÀÎÇÁ¶óÀÇ ÇýÅÃÀ» ¹Þ°í ÀÖÀ¸¸ç, ÀÓ»ó½ÃÇèÀ̳ª Àå½Ã°£ ÀÛ¿ëÇü ÁÖ»ç¿ä¹ý µî ÷´Ü HIV Ä¡·á¿¡ ´ëÇÑ ¾×¼¼½º°¡ ³Î¸® È®º¸µÇ°í ÀÖ½À´Ï´Ù. ¸ÞµðÄÉÀ̵å¿Í ¸ÞµðÄɾî¿Í °°Àº °Ç°­ º¸Çè Á¦µµ°¡ ³Î¸® º¸±ÞµÇ¾î ȯÀÚ´Â ÇÊ¿äÇÑ ±¸¸í Ä¡·á¸¦ ¹ÞÀ» ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¼Ò¸Å ¾à±¹, º´¿ø ½Ã¼³ ¹× ¿Â¶óÀÎ Ç÷§ÆûÀÇ ±¤¹üÀ§ÇÑ ³×Æ®¿öÅ©´Â HIV Ä¡·áÁ¦ÀÇ ¿øÈ°ÇÑ À¯Åë°ú ÀÔ¼ö¸¦ ÃËÁøÇϰí ȯÀÚ°¡ ÇÊ¿äÇÑ Ä¡·á¹ý¿¡ ½±°Ô ¾×¼¼½ºÇÒ ¼ö ÀÖµµ·Ï º¸ÀåÇÕ´Ï´Ù.

¼¼°èÀÇ Àΰ£ ¸é¿ª°áÇÌ ¹ÙÀÌ·¯½º(HIV) Ä¡·áÁ¦ ½ÃÀåÀº 2024³â¿¡ 390¾ï ´Þ·¯ÀÇ Æò°¡¾×¿¡ ´ÞÇß°í 2025³âºÎÅÍ 2034³â¿¡ °ÉÃÄ CAGR 3.5%¿¡¼­ ¾ÈÁ¤ÀûÀÎ ¼ºÀåÀ» ÀÌ·ê °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. ½ÃÀå È®´ëÀÇ ÁÖ¿ä ¿äÀÎÀº HIV °¨¿°·ü Áõ°¡, Ä¡·á¹ýÀÇ »ó´çÇÑ Áøº¸, Á¤ºÎÀÇ Áö¿øÃ¥, À¯¸®ÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ °áÇÕµÇ¾î ½ÃÀåÀÇ Áö¼ÓÀûÀÎ ¼ºÀå ±Ëµµ¸¦ ÃËÁøÇϴµ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù.

½ÃÀåÀº ÁÖ·Î ¾à¹°ÀÇ À¯Çü¿¡ µû¶ó ºê·£µå ÀǾàǰ°ú Á¦³×¸¯ ÀǾàǰÀ¸·Î ±¸ºÐµË´Ï´Ù. 2024³â¿¡´Â ºê·£µå ÀǾàǰÀÌ 74.5%¶ó´Â ´ëÆøÀûÀÎ Á¡À¯À²·Î ½ÃÀåÀ» ¼±µµÇßÀ¸¸ç, ±× ÀÌÀ¯´Â È¿´ÉÀÌ ÀÔÁõµÈ °Í, ¿À·£ ÀÓ»óÀû ½Å·Ú¼ºÀÌ ÀÖ´Â °Í, HIV Ä¡·á¿¡ À־ÀÇ ½ÇÀûÀÌ ½Å·ÚµÇ°í Àֱ⠶§¹®ÀÔ´Ï´Ù. ÇÕÁ¦´Â Åõ¾à ¿ä¹ýÀ» ´Ü¼øÈ­Çϰí ȯÀÚÀÇ Ä¡·á °èȹ¿¡ ´ëÇÑ Ãæ°ÝÀ» ³ôÀ̱⠶§¹®¿¡ ³Î¸® º¸±ÞµÇ¾î ÀÖ½À´Ï´Ù. ƯÈ÷ ¹ÙÀÌ·¯½º ¾çÀ» È¿°úÀûÀ¸·Î ¾ïÁ¦ÇÏ´Â º´¿ë ¿ä¹ý¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀº °è¼Ó ½ÃÀå ¼ö¿ä¸¦ °ßÀÎÇϰí ÀÖÀ¸¸ç, ¾ÕÀ¸·Îµµ ¾ÈÁ¤µÈ ½ÃÀå ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.

½ÃÀå À¯Åë ä³ÎÀº HIV Ä¡·áÁ¦ÀÇ µµ´Þ¹üÀ§¿Í Á¢±Ù¼ºÀ» ´õ¿í µ¸º¸ÀÌ°Ô ÇÕ´Ï´Ù. ÁÖ¿ä À¯Åë °æ·Î´Â ¾à±¹, ¼Ò¸Å ¾à±¹, ¿Â¶óÀÎ ¾à±¹, º´¿ø ¾à±¹ µîÀÔ´Ï´Ù. 2024³â¿¡´Â º´¿ø ¾à±¹ÀÌ 47.4%·Î °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. º´¿ø ¾à±¹Àº °í±Þ Ç× ·¹Æ®·Î ¹ÙÀÌ·¯½º ¿ä¹ý°ú ½ÅÁßÇÑ Åõ¿©°¡ ÇÊ¿äÇÑ ÁÖ»ç Ä¡·á¸¦ Æ÷ÇÔÇÏ¿©º¸´Ù ±¤¹üÀ§ÇÑ Àü¹® HIV Ä¡·áÁ¦¸¦ Á¦°øÇϱâÀ§ÇÑ ½Ã¼³À» °®Ãß°í ÀÖ½À´Ï´Ù. ÀÇ·á Àü¹®°¡ÀÇ °¨µ¶ÇÏ¿¡, º´¿ë ¿ä¹ýÀ» Æ÷ÇÔÇÑ ÃÖ÷´Ü Ä¡·á¸¦ Á¦°øÇÒ ¼ö Àֱ⠶§¹®¿¡ Àü¹®ÀûÀÎ Äɾî¿Í ¹è·Á°¡ ÇÊ¿äÇÑ È¯ÀÚ¿¡°Ô ¹Ù¶÷Á÷ÇÑ ¼±ÅÃÀÌ µÇ°í ÀÖ½À´Ï´Ù.

¹Ì±¹¿¡¼­ HIV Ä¡·áÁ¦ ½ÃÀåÀº 2024³â¿¡ 145¾ï ´Þ·¯¸¦ âÃâÇß½À´Ï´Ù. ÀÌ ³ª¶ó´Â °íµµ·Î ¹ß´ÞÇÑ ÀÇ·á ÀÎÇÁ¶óÀÇ ÇýÅÃÀ» ¹Þ°í ÀÖÀ¸¸ç, ÀÓ»ó½ÃÇèÀ̳ª Àå½Ã°£ ÀÛ¿ëÇü ÁÖ»ç¿ä¹ý µî ÷´Ü HIV Ä¡·á¿¡ ´ëÇÑ ¾×¼¼½º°¡ ³Î¸® È®º¸µÇ°í ÀÖ½À´Ï´Ù. ¸ÞµðÄÉÀ̵å¿Í ¸ÞµðÄɾî¿Í °°Àº °Ç°­ º¸Çè Á¦µµ°¡ ³Î¸® º¸±ÞµÇ¾î ȯÀÚ´Â ÇÊ¿äÇÑ ±¸¸í Ä¡·á¸¦ ¹ÞÀ» ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¼Ò¸Å ¾à±¹, º´¿ø ½Ã¼³, ÀÇ·á ±â°ü µîÀÇ ±¤¹üÀ§ÇÑ ³×Æ®¿öÅ©´Â ȯÀÚ¸¦ ±¸¸íÇÏ´Â µ¥ ÇÊ¿äÇÑ Ä¡·á¹ýÀ» Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¾÷°è ÀλçÀÌÆ®

Á¦4Àå °æÀï ±¸µµ

Á¦5Àå ½ÃÀå Ã߰衤¿¹Ãø : ¾àÁ¦ À¯Çüº°(2021-2034³â), 100¸¸ ´Þ·¯

Á¦6Àå ½ÃÀå Ã߰衤¿¹Ãø : ¾àÁ¦ Ŭ·¡½ºº°(2021-2034³â), 100¸¸ ´Þ·¯

Á¦7Àå ½ÃÀå Ã߰衤¿¹Ãø : À¯Åë ä³Îº°(2021-2034³â), 100¸¸ ´Þ·¯

Á¦8Àå ½ÃÀå Ã߰衤¿¹Ãø : Áö¿ªº°(2021-2034³â), 100¸¸ ´Þ·¯

Á¦9Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

KTH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Global Human Immunodeficiency Virus Therapeutics Market reached a valuation of USD 39 billion in 2024 and is projected to experience steady growth at a CAGR of 3.5% from 2025 to 2034. The market expansion is largely driven by the rising rates of HIV infections, significant advancements in treatment options, supportive government initiatives, and favorable regulatory approvals. These factors combined are playing a crucial role in fostering the market's ongoing growth trajectory.

Human Immunodeficiency Virus Therapeutics Market - IMG1

The market is primarily segmented by drug type into branded and generic drugs. In 2024, branded drugs led the market with a substantial share of 74.5%, attributed to their proven efficacy, long-standing clinical reliability, and trusted performance in HIV treatment. Fixed-dose combinations have been gaining widespread popularity, as they offer simplified dosing regimens that enhance patient adherence to treatment plans. Their key role in combination therapies, particularly for effectively suppressing viral loads, continues to drive demand in the market, ensuring consistent market growth in the years to come.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$39 Billion
Forecast Value$54.8 Billion
CAGR3.5%

The market's distribution channels further highlight the reach and accessibility of HIV therapeutics. The primary distribution segments include drug stores and retail pharmacies, online pharmacies, and hospital pharmacies. In 2024, hospital pharmacies held the largest share of the market, with a notable 47.4%. Hospital pharmacies are well-equipped to offer a broader selection of specialized HIV medications, including advanced antiretroviral therapies and injectable treatments that require careful administration. Their ability to provide cutting-edge treatments, including combination regimens, under the supervision of healthcare professionals makes them the preferred choice for patients who require specialized care and attention.

In the United States, the HIV therapeutics market generated USD 14.5 billion in 2024. The country benefits from a highly developed healthcare infrastructure that ensures widespread access to advanced HIV treatments, including clinical trials and long-acting injectable therapies. The widespread availability of health insurance programs, such as Medicaid and Medicare, further guarantees that patients can afford the life-saving therapies they need. Moreover, the extensive network of retail pharmacies, hospital facilities, and online platforms helps facilitate seamless distribution and availability of HIV therapeutics, ensuring that patients can easily access the treatments they require.

The global Human Immunodeficiency Virus (HIV) therapeutics market reached a valuation of USD 39 billion in 2024 and is projected to experience steady growth at a CAGR of 3.5% from 2025 to 2034. The market expansion is largely driven by the rising rates of HIV infections, significant advancements in treatment options, supportive government initiatives, and favorable regulatory approvals. These factors combined are playing a crucial role in fostering the market's ongoing growth trajectory.

The market is primarily segmented by drug type into branded and generic drugs. In 2024, branded drugs led the market with a substantial share of 74.5%, attributed to their proven efficacy, long-standing clinical reliability, and trusted performance in HIV treatment. Fixed-dose combinations have been gaining widespread popularity, as they offer simplified dosing regimens that enhance patient adherence to treatment plans. Their key role in combination therapies, particularly for effectively suppressing viral loads, continues to drive demand in the market, ensuring consistent market growth in the years to come.

The market's distribution channels further highlight the reach and accessibility of HIV therapeutics. The primary distribution segments include drug stores and retail pharmacies, online pharmacies, and hospital pharmacies. In 2024, hospital pharmacies held the largest share of the market, with a notable 47.4%. Hospital pharmacies are well-equipped to offer a broader selection of specialized HIV medications, including advanced antiretroviral therapies and injectable treatments that require careful administration. Their ability to provide cutting-edge treatments, including combination regimens, under the supervision of healthcare professionals makes them the preferred choice for patients who require specialized care and attention.

In the United States, the HIV therapeutics market generated USD 14.5 billion in 2024. The country benefits from a highly developed healthcare infrastructure that ensures widespread access to advanced HIV treatments, including clinical trials and long-acting injectable therapies. The widespread availability of health insurance programs, such as Medicaid and Medicare, further guarantees that patients can afford the life-saving therapies they need. Moreover, the extensive network of retail pharmacies, hospital facilities, and on

Table of Contents

Chapter 1 Methodology & Scope

Chapter 2 Executive Summary

Chapter 3 Industry Insights

Chapter 4 Competitive Landscape, 2024

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 – 2034 ($ Mn)

Chapter 6 Market Estimates and Forecast, By Drug Class, 2021 – 2034 ($ Mn)

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

Chapter 9 Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â